Valneva SE (VALN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Valneva SE (VALN) closed at USD 5.66 on 2026-10-14, a change of -37.9 % over the past year, with a market capitalization of USD 560.41M.

Valneva SE recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Valneva SE key figures

Previous close

USD 5.66 (2026-10-14)

1-year change

-37.9 %

Market cap

USD 560.41M

Enterprise value

USD 649.11M

P/E ratio (trailing)

-2.70

P/E ratio (forward)

4.97

EPS (trailing)

-2.19

EPS (forward)

1.19

PEG ratio

n/a

Price to book

6.17

Revenue growth

-27.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.96

Employees

620

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Valneva SE and compare it with other stocks.